Psychedelics PharmAla Biotech gets Health Canada approval to export large MDMA shipment to the U.K. The company believes this to be the largest shipment of MDMA the government department has ever approved Rowan DunneJanuary 24, 2023
Psychedelics Apex Labs doses first patient in Veterans take-home psilocybin drug trial The development marks a 'watershed moment for psilocybin research' says the company's CEO Rowan DunneJanuary 18, 2023
Psychedelics Biomind Labs develops sublingual psychedelic drug to treat Alzheimer’s The under-the-tongue drug candidate will be studied in a Phase II clinical trial prior to commercialization Rowan DunneDecember 30, 2022
Psychedelics Awakn set to research ketamine for alcohol use disorder The trial will be held at 7 NHS sites in the U.K. with the NIHR funding 66% of the cost Rowan DunneDecember 14, 2022
Canada Health Canada provides guidance for clinical trials on psychedelics The notice to stakeholders outlined risk management and consent expectations for the study of psychoactive drugs Rowan DunneDecember 5, 2022
Cannabis U.S. senators introduce bill to improve access to psilocybin and MDMA The bill would reduce 'unreasonably burdensome rules and regulations' Rowan DunneNovember 23, 2022
Canada PharmAla and Mindset enter psilocybin distribution agreement PharmAla will have exclusive rights to resell Mindset's cGMP psilocybin to designated researchers Rowan DunneNovember 16, 2022
Psychedelics Mindset Pharma develops patent-pending new technology Company announces development of novel intranasal formulation with promising efficacy Rowan DunneJune 30, 2022
Industry update MagicMed attracts investors to advance library of psychedelic derivatives After raising $8.1M, the Calgary company filed 12 patents and launched a candidate selection program for novel psychedelic mental health treatments Jared GnamDecember 23, 2020